Protocol Specific Research Support

方案特定研究支持（PSRS）的目的是帮助VICC继续致力于高质量、科学上有价值的转化研究，以促成进一步的试验和/或获得同行评审支持。资源分配委员会（RAC）将这些重要的资金分配给值得进行的临床试验。James Whitlock，医学博士，儿科肿瘤学家，RAC主席，其中包括VICC主任和副主任沿着以及来自内科肿瘤学、外科肿瘤学和放射肿瘤学的代表。研究者发起的可行性/I期或初步试验根据独立的内部或外部科学审查进行科学价值判断。标准包括试验是否源于VICC内进行的临床前工作，是否可能导致外部同行评审资金，是否可能导致更大规模的多机构关键11期或111期试验，或者试验是否具有独特的实验室相关性整合到其主要或次要目的/目标中。职业发展目标（优先考虑初级教师）也被考虑。 在上一个赠款周期，VICC承诺提供慈善基金，以补充PSRS基金，扩大RAC支持赠款支持有限的试验的能力，并资助一些相关的探索性分析研究。对这两类基金的全面审查至少每季度举行一次会议，并根据需要举行特别会议。可通过网络工具编写信息包，其中包括方案、方案的相关性、预算缺口和理由以及今后的方向，以便提交咨询和咨询委员会，而且维也纳国际中心的所有调查员都可获得资金。在上一个资助周期中，有13项试验符合PSRS基金的资格，其中4项仍在开放，1项提前关闭，3项不建议进一步开发，1项导致11期试验获得试点资金（也来自RAC），1项有进一步的LOI，1项现在是ECOG试验的一部分，2项正在等待最终数据分析。目前有八项试验研究五个疾病的网站正在考虑PSRS的资金，包括两个试验开发的学员。 因此，PSRS的资金是至关重要的转化研究工作在范德比尔特完成。我们已经成功地资助了试点研究，并在下一个赠款周期预计将继续资助高影响力的研究者发起的试验。

The purpose of Protocol Specific Research Support (PSRS) is to help VICC continue its commitment to high quality, scientifically meritorious translational research intended to lead to further trials and/or to lead to peer-reviewed support. The Resource Allocation Committee (RAC) distributes these important funds to deserving clinical trials. James Whitlock, M.D., a pediatric oncologist, chairs the RAC, which includes the VICC Director and Deputy Director along with representatives from Medical Oncology, Surgical Oncology, and Radiation Oncology. Investigator-initiated feasibility/Phase I or pilot trials are judged for scientific merit based on an independent internal or external scientific review. The criteria include whether the trial originates from preclinical work performed within the VICC, the potential to lead to external peer-reviewed funding, the potential to lead to a larger multi-institutional pivotal Phase 11 or Phase 111 trial, or whether the trial has unique laboratory correlates integrated into its primary or secondary aims/objectives. Career development goals (preferential consideration for junior faculty) are also considered. During the last grant cycle, the VICC committed philanthropy funds to supplement the PSRS funds broadening RAC's ability to support trials that have limited grant support and to fund some correlative studies for exploratory analysis. Full review for both types of funds are carried out in at least quarterly meetings, with ad hoc meetings held based on need. Preparation of an information packet including the protocol, its relevance, budget shortfall and rationale, and future directions can be performed from the web-based tool for RAC submission and funds are available to all VICC investigators. In the last grant cycle, 13 trials qualified for PSRS funds, four of which are still open, one closed early, three were not recommended for further development, one led to a phase 11 trial that received pilot funding (also from RAC), one has a further LOI, one is now part of an ECOG trial and two are awaiting final data analysis. There are currently eight trials studying five disease sites under consideration for PSRS funding, including two trials developed by trainees. Thus, PSRS funding is crucial to the translational research work done at Vanderbilt. We have been successful at funding pilot studies and in the next grant cycle anticipate continuing to fund high-impact investigator initiated trials.